CAR-T-cell cancer therapy uses special T-cells that are specifically directed towards tumor antigens, the so-called (CAR)-T-cells. These cells trigger a targeted immune response that helps the body recognize and fight cancer cells. But, like other cancer therapies, the treatment can cause unwanted side effects, such as affecting heart function. Scientists from the Medical Faculty of the University
Clinical trial results promising for people with the debilitating disorder A clinical trial at UC Davis Health and six other sites showed that a cellular therapy offers promise for patients with late-stage Duchenne muscular dystrophy (DMD), a rare genetic disorder causing muscle loss and physical impairments in young people. The therapy appears to be safe and effective
CAR T therapy has had enormous impact in some areas of oncology, and notable efforts are underway to extend the success to additional forms of cancer. However, the use of engineered T cells may be evenmore attractive for disorders other than cancer for several reasons. This review analyses different opportunities and future directions. First, for
Researchers from Tokyo Medical and Dental (TMDU) develop artificial tendons in vitro from human stem cells that could fix common tendon injuries such as Achilles tendon rupture. Tendons are tissues that connect muscles to bones and are important for movement and locomotion. Injuries to tendons are quite common, with millions of people – particularly athletes
Phase 3 clinical trial included children younger than 12 years Over 90 percent of patients with transfusion-dependent thalassemia, an inherited blood disorder, no longer needed monthly blood transfusions years after receiving gene therapy, according to an international Phase 3 clinical trial that for the first time included children younger than 12 years of age. Twenty-two patients
Experts say careful application of advanced tech could usher in a golden age of healthcare New technologies could enable medicine to progress in leaps and bounds, but only with the right regulatory and ethical frameworks. That was one of the messages from panelists discussing the future of medicine at the Science|Business conference Horizon Europe: The first assessment as
In this review, it’s provided an overview of the major mechanisms used by tumor cells to evade immune defenses and are critically exposed the most optimistic engineering strategies to make CAR-T cell therapy a solid option for solid tumors. CAR-T cell based cell therapy is a moving field, which showed impressive results in hematopoietic cancer
This eBook gauges shifting expectations for the gene therapy industry amid the COVID-related uncertainties and clinical setbacks of the past couple years. BioProcess Insider founding editor Dan Stanton reports on the January 2022 Phacilitate Advanced Therapies Week event, specifically a standing presentation on the 10 most important industry drivers from the past year. Since 2017, advancements in
Two babies have received the first-ever gene therapy for Tay-Sachs disease after over 14 years of development. Tay-Sachs is a severe neurological disease caused by a deficiency in an enzyme called HexA. This enzyme breaks down a fatlike substance that normally exists in very small, harmless amounts in the brain. Without HexA, however, this fatlike substance can accumulate
Heart disease remains the leading cause of death in the world. One reason is that unlike other tissues, such as bone and skin, the heart has remarkably poor regenerative capability after an injury such as a heart attack. Scientists have therefore searched for heart cells that have regenerative properties. A new study by the Yoshinori
